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Introduction
Streptococcus pneumoniae (the pneumococcus) is an encapsulated Gram-positive bacterium with ninety-one different capsules or serotypes identified so far. This bacterium is a common colonizer of the nasopharynx in children, but can also cause life-threatening diseases such as pneumonia and invasive pneumococcal diseases (i.e. sepsis and meningitis), killing more than 2 millions people in the world every year and leaving severe sequelae in many children [1] .
The Toll-Like Receptors (TLRs) play an important role in host defense against microbial infections including pneumococci [2] . They recognize conserved bacterial structures or also called pathogen-associated molecular patterns (PAMPs). Upon recognition of their cognate ligands, TLRs can initiate two distinct signaling cascades, the MyD88-dependent or the MyD88-independent, leading to either the production of proinflammatory cytokines or the production of type I interferons (IFNs) [2] . Pneumococci express several PAMPs such as lipoteichoic acids (LTA), pneumolysin, and hypomethylated DNA containing CpG motifs that are ligands for TLR2, TLR4 and TLR9 respectively [3] [4] [5] . Recent studies showed that mice deficient in TLR2 are only marginally affected in their susceptibility to invasive pneumococcal disease, while both TLR4 and TLR9 play important roles in controlling pneumococcal colonization and the early clearance of bacteria from the lower respiratory tract. We have shown that MyD88-deficiency in mice results in uncontrolled bacterial growth in the airways leading to rapid bacterial dissemination into the bloodstream resulting in systemic infection [4] . The increased susceptibility of MyD88-deficient mice is illustrated by an impaired local production of proinflammatory cytokines and chemokines [4] .
Chemokines is a large family of peptides unified by their ability to exert receptor-dependent regulation of leukocyte-trafficking during both health and disease [6] .
They are divided into four groups, C, CC, CXC, and CX 3 C respectively, depending on the arrangement of conserved cysteine-motifs in their NH 2 -terminal region. In addition to their interactions with leukocytes, chemokines regulate other events during inflammation, for example angiogenesis and angiostasis, and yet some have potent antibacterial activity themselves [7] . The monokine induced by IFN-γ, MIG/CXCL9 belongs to the CXC chemokine family and is expressed by epithelial cells and granulocytes during Th 1 -polarized inflammation [8] . It exhibits strong antibacterial activity in vitro against several pathogens [9, 10] . Recently, we found MIG/CXCL9-dependent antibacterial activity against S. pyogenes at the surface of IFN-γ stimulated pharyngeal epithelial cells in vitro [9] . This led us to investigate the expression and a possible role for MIG/CXCL9 in vivo during mucosal airway infection caused by Streptococcus pneumoniae.
In this study, two murine models of pneumococcal pneumonia (non-lethal resolving and acute pneumonia) were used to investigate potential key roles for MIG/CXCL9 in host defense functions. We show that MIG/CXCL9 is expressed in the lungs upon pneumococcal infection in a MyD88-dependent manner. We also demonstrate that in vitro MIG/CXCL9 has antibacterial activity against S. pneumoniae. However, we were unable to demonstrate that MIG/CXCL9 is essential for microbial clearance and host survival in vivo.
Materials and methods

Bacterial strain and culture conditions
Streptococcus pneumoniae TIGR4 is a clinical encapsulated isolate of serotype 4 (ATCC BAA-334; http://www.tigr.org). For in vitro experiments, bacteria were grown overnight from frozen stocks on blood agar plates at 37°C and 5% CO 2 . Colonies were grown in TH (Todd-Hewitt) broth supplemented with 0.5% yeast extract to OD 600nm =0.4-0.5. Appropriate dilutions were made to obtain the desired concentration. The concentrations were retrospectively confirmed by counting colony-forming units (cfu) on blood agar plates.
Mice and infection models
C57BL/6 (wt), ICE-, TLR4-, TLR9-and MIG/CXCL9-deficient mice (six to eight weeks old) were kept under pathogen-free conditions. The ICE knock-out (KO) mice are unable to release functional IL-1 and IL-18. All KO mice had been backcrossed for at least seven generations on the C57BL/6 background. The animals were housed five per cage in a standardized 12 h light/dark cycle and received commercial food and water ad libitum. All the experiments were conducted in conformity with the European Communities Council Directive 86/609/EEC and the Swedish Animal Protection Legislation. All animal groups were age and sex matched for each experiments. For the non-lethal resolving pneumonia model, mice were inoculated intranasally (i.n.) with vehicle (PBS) or TIGR4 (10 5 cfu/mouse) in a volume of 20 µl. For the acute pneumonia/bacteremia model, mice were infected i.n.
with vehicle (PBS) or TIGR4 (10 7 cfu/mouse). The health status and survival of the mice, including sampling from blood, lungs and nasopharyngeal-tracheal lavages (NAL) were performed as previously described [4] . Briefly, to evaluate bacteremia, blood samples (5 µl) were obtained from the tail vein at various time-points and used for serial plating to quantify viable bacteria by cfu. The lungs were removed and homogenized in 1 ml of PBS containing a complete cocktail protease inhibitor (Roche Diagnostics Scandinavia) and used in serial dilutions to quantify viable bacteria by plating on blood agar plates. The homogenates were centrifuged at 4°C
for 30 min at 5000 rpm and the supernatants were stored at -80°C for later cytokine and chemokine analysis. NAL were performed in animals post-mortem with a 20-gauge catheter inserted into the proximal trachea, flushing the nasopharynx through the trachea and the nares with 200 µl PBS and used in serial plating to quantify viable bacteria.
Proteins and antibodies
Recombinant human and murine MIG/CXCL9 were purchased from Peprotech, Rocky Hill, NJ. The polyclonal goat antibody against MIG/CXCL9, the goat isotype control, human and murine TNF-α as well as human and murine IFN-γ were obtained from R&D Systems, Abingdon, UK.
In vitro killing assays
Bronchial epithelial killing
Human primary bronchial epithelial cells (HBEC) were obtained from Lonza
Copenhagen. HBEC were seeded in 24-well tissue culture plates and cultured to confluence (1 x 10 6 cells/well) in MEM supplemented with 10% heat-inactivated fetal bovine serum and penicillin/streptomycin (100 U/ml and 0.1 ng/ml respectively) at 37°C in an atmosphere containing 5% CO 2 with 100% relative humidity. HBEC were washed with MEM and then incubated in medium alone (control) or stimulated with IFN-γ (10 ng/ml), TNF-α (10 ng/ml) or IFN-γ (10 ng/ml) + TNF-α (10 ng/ml) for 24 h.
Subsequently, 50 µl of bacteria (TIGR4; 2x10 6 /ml in incubation buffer; MOI=0.1) was layered on top of the epithelial cells. This was followed by centrifugation at 300 x g for 10 minutes to promote cell-bacteria interaction and incubation for 1 h at 37°C.
Trypsin (2.5 mg/ml in PBS) was used to detach the cells from the wells and Triton X-100 (0.025% in PBS) was added to lyse the cells and release internalized bacteria.
Bacterial killing was determined by viable counts after plating on blood agar plates.
MIG/CXCL9 killing
S. pneumoniae strain TIGR4 was grown to mid-logarithmic phase (OD 620nm = 0.4-0.5) in TH broth supplemented with 0.5 % yeast extract, washed, and diluted in 10 mM Tris (pH 7.5) containing 5 mM glucose (incubation buffer) to a concentration of 1%. Fifty microliters of bacteria (2 x 10 6 cfu/ml) were incubated with human or murine MIG/CXCL9 at different concentration or in buffer alone for 2 h at 37°C. To quantitate bactericidal activity, serial dilutions of the incubation mixtures were plated on blood agar plates, and the number of cfu was determined.
Stimulation of human and murine bronchial epithelial cells
MLE-12, a murine bronchial epithelial cell line (a gift from Dr. Jeffrey Whitsett,
Children's Hospital Medical Center, Cincinnati, USA) was cultured to semi confluent layers in DMEM+GlutaMAX supplemented with 10% heat-inactivated fetal bovine serum and penicillin/streptomycin (100 U/ml and 0.1 ng/ml respectively) at 37°C in an atmosphere containing 5% CO 2 with 100 % relative humidity. HBEC were seeded in 24-well tissue culture plates and cultured to confluence. Cells were stimulated in 24-well plates for 24 h as follows: culture medium (control), IFN-γ (10 ng/ml), TNF-α (10 ng/ml) and IFN-γ (10 ng/ml) + TNF-α (10 ng/ml). The supernatants were collected and the MIG/CXCL9 concentration was quantified using ELISA.
Determination of cytokine and chemokine levels
TNF-α, IFN-γ and MIG/CXCL9 of lung homogenates were measured using commercial ELISA kits (R&D Systems, Abingdon, UK). According to the manufacturer, the ELISAs are specific and do not recognize related peptides. The detection limit for the ELISA was set to 30 pg/ml and the samples were diluted so that values could be calculated from the linear part of the standard curves.
Modeling a predictive structure of murine and human MIG/CXCL9
Sequence alignment
The pairwise sequence comparison and alignment between mouse and human CXCL9 were generated using ClustalW [11] .
Molecular modeling
Model structures of full length human and mouse MIG/CXCL9 (accession number Q07325 and P18340, respectively) were generated as comparative homology models using the NMR structure of truncated human MIP2-α (Gro-β) with Protein Data Bank code 1QNK as template [12] . Residues 23-125 of human MIG/CXCL9
were aligned against the sequence of MIP2-α creating an alignment where MIP2-α residues 39-107 matched to human MIG/CXCL9 residues 27-96 with only one gap at threonine 40 of human MIG/CXCL9. The sequence identity was 49 %. The modeling was performed using the program MODELLER version 9v7 [13] [14] [15] . Ten models were generated using the automodel class and the model with the lowest DOPE assessment score were selected. 
Negative staining and transmission electron microscopy
Bacteria were incubated for 2 h at 37°C in incubation buffer, in the absence or presence of MIG/CXCL9 (2.4 µg/ml). Negative staining of the bacteria was performed with 0.75% uranyl formate. Specimens were examined in a Jeol 1200 EX transmission electron microscope operated at 60 kV accelerating voltage.
Statistical evaluation
Significant differences were evaluated using the Student's t test. The survival was analyzed by Kaplan-Meier log rank test.
Results
IFN-γ stimulated human bronchial epithelial cells are bactericidal
Human bronchial epithelial cells (HBEC) express high levels of MIG/CXCL9 in response to IFN-γ stimulation [8] . We confirmed that HBEC produce high levels of MIG/CXCL9 in response to IFN-γ, but not in response to TNF-α stimulation.
Moreover, a twofold increase in MIG/CXCL9 production was observed when IFN-γ and TNF-α were combined, highlighting a synergistic effect of IFN-γ and TNF-α on MIG/CXCL9 expression (Fig.1A) . After stimulation with IFN-γ and TNF-α and IFN-γ combined, but not with TNF-α alone, HBEC also exhibited antibacterial activity as compared to non-stimulated control cells (Fig.1B) . The antibacterial activity of HBEC correlated with high levels of MIG/CXCL9 production suggesting a direct causality between MIG/CXCL9 production and the antibacterial activity. Controls experiments showed that neither IFN-γ nor TNF-α themselves or combined have any antimicrobial activity per se (data not shown).
Taken together, our data demonstrate that during an inflammatory state, HBEC are antibacterial against S. pneumoniae, possibly through the production of MIG/CXCL9.
Human and murine MIG/CXCL9 kill Streptococcus pneumoniae efficiently in vitro
To test whether MIG/CXCL9 is antibacterial against S. pneumoniae, we performed in vitro killing assays. Human MIG/CXCL9 displayed a strong and dose-dependent antibacterial activity against S. pneumoniae TIGR4 strain ( Fig. 2A) , which can be blocked with a polyclonal anti-MIG/CXL9 antibody (data not shown). Investigation of bacterial morphology using electron microscopy and negative staining showed that MIG/CXCL9 exposure caused lysis and leakage of intracellular content (Fig. 2B ).
Sequence alignments showed that human and murine MIG/CXCL9 are highly conserved with an overall of 67 % identity and 80 % similarity on the amino acid level (Fig. 2C) . Structural prediction revealed that both molecules have a similar threedimensional structure consisting of three anti-parallel β-sheets and amphipatic α-helix with unordered tail regions (Fig. 2D) . Recombinant murine MIG/CXCL9 showed a potent antibacterial activity against TIGR4 ( Fig. 2A) , demonstrating that the antibacterial function is conserved between the murine and human molecules.
Cytokine-stimulated murine bronchial epithelial cells express high levels of MIG/CXCL9
Murine lung epithelial cells (MLE-12) produced high levels of MIG/CXCL9 in response to IFN-γ, but not TNF-α stimulation. A 10-fold increase in MIG/CXCL9
production was observed when IFN-γ and TNF-α were combined (Fig. 3) demonstrating the same synergistic effect of IFN-γ and TNF-α on MIG/CXCL9 expression as described above for the HBEC. Our data confirm that inflamed murine bronchial epithelial cells are capable of producing MIG/CXCL9.
MIG/CXCL9 is produced in the lungs during pneumococcal pneumonia
Wild-type (wt) mice were infected intranasally (i.n.) with TIGR4 strain. We found that TNF-α, IFN-γ and MIG/CXCL9 were expressed in the lungs during infection in vivo.
Both TNF-α and IFN-γ expression was maximal at 12 h post infection (pi) and remained stable up to 24 h pi, while MIG/CXCL9 expression peaked 24 h after inoculation; a sequential expression confirming that IFN-γ and TNF-α production precede that of MIG/CXCL9 (Fig. 4A) . Histopathological examination and immunohistochemistry staining showed the presence of professional immune cells into the lung tissue and the local production of MIG/CXCL9 in the airways during infection (Fig. 4B) . Thus, TNF-α, IFN-γ and MIG/CXCL9 are expressed in the lungs upon pneumococcal infection, suggesting important roles of these proinflammatory mediators in host protection.
MyD88-signalling is required for MIG/CXCL9 production in the lungs
The central adaptor MyD88 of the TLRs signaling has a key role during pneumococcal pneumonia [3, 4] . Upon pneumococcal challenge, the local expression of IL-12 but not IFN-γ was dependent on the MyD88 signaling pathway ( Fig. 5A and 5B). Next, we investigated the contribution of MyD88 and TLRs signaling in pneumococci-induced MIG/CXCL9 expression. MyD88 KO mice showed significantly lower levels of MIG/CXCL9 in the lungs as compared with wt mice (Fig.   5C ). We found no significant difference in MIG/CXCL9 production in the lungs of the single TLRs KO (Fig. 5C ). Taken together, our data show that MIG/CXCL9 production in the lungs upon pneumococcal challenge is dependent mainly on the MyD88 signaling pathway.
MIG/CXCL9 is not essential for survival in airway infection caused by
Streptococcus pneumoniae
To study the mucosal antibacterial function of MIG/CXCL9 in vivo, we infected wt and MIG/CXCL9 KO mice i.n. with a low infectious dose of TIGR4 (10 5 cfu), which leads to a non-lethal resolving pneumonia and colonization up to 15 days [3] . No difference in survival or nasopharyngeal colonization was observed between wt and KO mice (Fig. 6) . In an acute pneumonia model, wt and MIG/CXCL9 KO mice were infected i.n. with a high infectious dose of TIGR4 (10 7 cfu). In this model, the bacteria can disseminate from the lungs to the bloodstream and the animal succumbs to an overwhelming systemic infection. The survival of the mice in the two groups was almost identical over time following initiation of the infection (Fig. 6 ). Bacterial loads in the blood, in the NAL and in the lungs were equivalent in both groups (data not shown). Thus, the absence of MIG/CXCL9 does not affect clearance of pneumococci from the upper and lower respiratory tract or susceptibility to invasive infection in a murine model of S. pneumoniae infection.
Discussion
In this work, we investigated the expression and the possible importance for MIG/CXCL9 in mucosal host defense during respiratory infections caused by S.
pneumoniae.
The respiratory epithelium is continuously exposed to inhaled particles and pathogens. It is an important source of mediators of lung inflammation such as chemokines, which are crucial for the recruitment of leukocytes into sites of infection.
Therefore, they constitute an important first line of defense against airborne infections [17] . Human bronchial epithelial cells (HBEC) express high levels of MIG/CXCL9 in response to IFN-γ stimulation [8] . We showed that primary HBEC stimulated with IFN-γ exhibit antibacterial activity against S. pneumoniae. immune system in the control and clearance of this pathogen [24, 25] .
In conclusion, we could identify an antimicrobial role for MIG/CXCL9 in vitro but not in vivo, most likely explained by an important redundancy among key molecules regulating host defense. 
